Document Type

Review

Publication Date

7-1-2018

Keywords

Inflammation, Lipid mediators, Lipoxygenase, Macrophages, Neutrophils, Omega-3 fatty acids, Resolution, Resolvins

Digital Object Identifier (DOI)

https://doi.org/10.1016/j.biotechadv.2018.02.014

Abstract

Fatty acid drug discovery (FADD) is defined as the identification of novel, specialized bioactive mediators that are derived from fatty acids and have precise pharmacological/therapeutic potential. A number of reports indicate that dietary intake of omega-3 fatty acids and limited intake of omega-6 promotes overall health benefits. In 1929, Burr and Burr indicated the significant role of essential fatty acids for survival and functional health of many organs. In reference to specific dietary benefits of differential omega-3 fatty acids, docosahexaenoic and eicosapentaenoic acids (DHA and EPA) are transformed to monohydroxy, dihydroxy, trihydroxy, and other complex mediators during infection, injury, and exercise to resolve inflammation. The presented FADD approach describes the metabolic transformation of DHA and EPA in response to injury, infection, and exercise to govern uncontrolled inflammation. Metabolic transformation of DHA and EPA into a number of pro-resolving molecules exemplifies a novel, inexpensive approach compared to traditional, expensive drug discovery. DHA and EPA have been recommended for prevention of cardiovascular disease since 1970. Therefore, the FADD approach is relevant to cardiovascular disease and resolution of inflammation in many injury models. Future research demands identification of novel action targets, receptors for biomolecules, mechanism(s), and drug-interactions with resolvins in order to maintain homeostasis.

Was this content written or created while at USF?

No

Citation / Publisher Attribution

Biotechnology Advances, v. 36, issue 4, p. 935-953

This article is the post-print author version. Final version available at: https://doi.org/10.1016/j.biotechadv.2018.02.014

Download

Share

COinS